PMC:7519301 / 99-866 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":459,"end":466},"obj":"Body_part"},{"id":"T2","span":{"begin":493,"end":500},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma84116"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"The rapid spread of the virus causing COVID-19, SARS-CoV-2, raises questions about the possibility of a universally effective vaccine. The virus can mutate in a given individual, and these variants can be propagated across populations and time. To understand this process, we analyze 18,514 SARS-CoV-2 sequences sampled since December 2019. We find that neutral evolution, rather than adaptive selection, can explain the rare mutations seen across SARS-CoV-2 genomes. In the immunogenic Spike protein, the D614G mutation has become consensus, yet there is no evidence of mutations affecting binding to the ACE2 receptor. Our results suggest that, to date, the limited diversity seen in SARS-CoV-2 should not preclude a single vaccine from providing global protection."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T3","span":{"begin":38,"end":46},"obj":"Disease"},{"id":"T4","span":{"begin":48,"end":56},"obj":"Disease"},{"id":"T5","span":{"begin":48,"end":52},"obj":"Disease"},{"id":"T6","span":{"begin":291,"end":299},"obj":"Disease"},{"id":"T7","span":{"begin":291,"end":295},"obj":"Disease"},{"id":"T8","span":{"begin":448,"end":456},"obj":"Disease"},{"id":"T9","span":{"begin":448,"end":452},"obj":"Disease"},{"id":"T10","span":{"begin":686,"end":694},"obj":"Disease"},{"id":"T11","span":{"begin":686,"end":690},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"The rapid spread of the virus causing COVID-19, SARS-CoV-2, raises questions about the possibility of a universally effective vaccine. The virus can mutate in a given individual, and these variants can be propagated across populations and time. To understand this process, we analyze 18,514 SARS-CoV-2 sequences sampled since December 2019. We find that neutral evolution, rather than adaptive selection, can explain the rare mutations seen across SARS-CoV-2 genomes. In the immunogenic Spike protein, the D614G mutation has become consensus, yet there is no evidence of mutations affecting binding to the ACE2 receptor. Our results suggest that, to date, the limited diversity seen in SARS-CoV-2 should not preclude a single vaccine from providing global protection."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":24,"end":29},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T3","span":{"begin":102,"end":103},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T4","span":{"begin":139,"end":144},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T5","span":{"begin":159,"end":160},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T6","span":{"begin":521,"end":524},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T7","span":{"begin":717,"end":718},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The rapid spread of the virus causing COVID-19, SARS-CoV-2, raises questions about the possibility of a universally effective vaccine. The virus can mutate in a given individual, and these variants can be propagated across populations and time. To understand this process, we analyze 18,514 SARS-CoV-2 sequences sampled since December 2019. We find that neutral evolution, rather than adaptive selection, can explain the rare mutations seen across SARS-CoV-2 genomes. In the immunogenic Spike protein, the D614G mutation has become consensus, yet there is no evidence of mutations affecting binding to the ACE2 receptor. Our results suggest that, to date, the limited diversity seen in SARS-CoV-2 should not preclude a single vaccine from providing global protection."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":493,"end":500},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"The rapid spread of the virus causing COVID-19, SARS-CoV-2, raises questions about the possibility of a universally effective vaccine. The virus can mutate in a given individual, and these variants can be propagated across populations and time. To understand this process, we analyze 18,514 SARS-CoV-2 sequences sampled since December 2019. We find that neutral evolution, rather than adaptive selection, can explain the rare mutations seen across SARS-CoV-2 genomes. In the immunogenic Spike protein, the D614G mutation has become consensus, yet there is no evidence of mutations affecting binding to the ACE2 receptor. Our results suggest that, to date, the limited diversity seen in SARS-CoV-2 should not preclude a single vaccine from providing global protection."}

{"project":"LitCovid-PubTator","denotations":[{"id":"10","span":{"begin":487,"end":492},"obj":"Gene"},{"id":"11","span":{"begin":606,"end":610},"obj":"Gene"},{"id":"12","span":{"begin":48,"end":58},"obj":"Species"},{"id":"13","span":{"begin":291,"end":301},"obj":"Species"},{"id":"14","span":{"begin":448,"end":458},"obj":"Species"},{"id":"15","span":{"begin":686,"end":696},"obj":"Species"},{"id":"16","span":{"begin":38,"end":46},"obj":"Disease"},{"id":"17","span":{"begin":506,"end":511},"obj":"Mutation"}],"attributes":[{"id":"A10","pred":"tao:has_database_id","subj":"10","obj":"Gene:43740568"},{"id":"A11","pred":"tao:has_database_id","subj":"11","obj":"Gene:59272"},{"id":"A12","pred":"tao:has_database_id","subj":"12","obj":"Tax:2697049"},{"id":"A13","pred":"tao:has_database_id","subj":"13","obj":"Tax:2697049"},{"id":"A14","pred":"tao:has_database_id","subj":"14","obj":"Tax:2697049"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"Tax:2697049"},{"id":"A16","pred":"tao:has_database_id","subj":"16","obj":"MESH:C000657245"},{"id":"A17","pred":"tao:has_standard_notation","subj":"17","obj":"p.D614G"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The rapid spread of the virus causing COVID-19, SARS-CoV-2, raises questions about the possibility of a universally effective vaccine. The virus can mutate in a given individual, and these variants can be propagated across populations and time. To understand this process, we analyze 18,514 SARS-CoV-2 sequences sampled since December 2019. We find that neutral evolution, rather than adaptive selection, can explain the rare mutations seen across SARS-CoV-2 genomes. In the immunogenic Spike protein, the D614G mutation has become consensus, yet there is no evidence of mutations affecting binding to the ACE2 receptor. Our results suggest that, to date, the limited diversity seen in SARS-CoV-2 should not preclude a single vaccine from providing global protection."}

{"project":"LitCovid-sentences","denotations":[{"id":"T3","span":{"begin":0,"end":134},"obj":"Sentence"},{"id":"T4","span":{"begin":135,"end":244},"obj":"Sentence"},{"id":"T5","span":{"begin":245,"end":340},"obj":"Sentence"},{"id":"T6","span":{"begin":341,"end":467},"obj":"Sentence"},{"id":"T7","span":{"begin":468,"end":620},"obj":"Sentence"},{"id":"T8","span":{"begin":621,"end":767},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The rapid spread of the virus causing COVID-19, SARS-CoV-2, raises questions about the possibility of a universally effective vaccine. The virus can mutate in a given individual, and these variants can be propagated across populations and time. To understand this process, we analyze 18,514 SARS-CoV-2 sequences sampled since December 2019. We find that neutral evolution, rather than adaptive selection, can explain the rare mutations seen across SARS-CoV-2 genomes. In the immunogenic Spike protein, the D614G mutation has become consensus, yet there is no evidence of mutations affecting binding to the ACE2 receptor. Our results suggest that, to date, the limited diversity seen in SARS-CoV-2 should not preclude a single vaccine from providing global protection."}